【关键词】肺肿瘤; 表皮生长因子受体基因20号外显子插入; 基因检测; 专家共识 非小细胞肺癌(non-small cell lung cancer,NSCLC)是最常见的肺癌类型,约占肺癌的82%。NSCLC靶向治疗的重大进展显著提高了客观缓解率(objective response rate...
2024年11月29日,同济大学医学院附属东方医院周彩存教授牵头多位专家在Nature Reviews Clinical Oncology发表题为“The changing treatment landscape of EGFR-mutant non-small-cell lung cancer”的综述,全面回顾和分析EGFR突变NSCLC治疗领域...
1.1.1吉非替尼 在一线治疗中,3 项研究(IPASS,WJTOG3405 和NEJ002)结果显示:在晚期EGFR 突变非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,与化疗相比,吉非替尼明显改善无进展生存(progression-freesurvival, PFS)和客观缓解率(objective response rate,ORR),然而总生存(overall survival, OS)无明显差异。
[1]AKAMATSU H, TOI Y, HAYASHI H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clin...
●20号外显子的获得性变异导致对TKI治疗耐受 ●EGFR过表达在40~80%的患者中出现,但是在预测作用方面尚存争议 ●EGFRvIII的持续激活在鳞癌中被发现,因此EGFRvIII是治疗这一非小细胞肺癌亚种的潜在位点 原文:The Landscape ofEGFRPathways and Personalized Management of Non-small-cell Lung Cancer...
谢谢!参考资料 1.Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer | NEJM 2.Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study. | Journal of Clinical Oncology (ascopubs.org)
[2] Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy [3] 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient ...
[1]. Chan, B.A. and B.G. Hughes, Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res, 2015. 4(1): p. 36-54. [2]. Costa, D.B., Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving...
关键词 伏美替尼;表皮生长因子受体;酪氨酸激酶抑制剂;非小细胞肺癌;突变;有效性;安全性 Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer GU Hangye,LYU Qing,CHEN Yong(Key Specialty of Clinical Pharmacy,the First Affiliated Hospital of Guangdong Pharmaceutical University,...
导读:EGFR外显子20插入(20ins)阳性非小细胞肺癌(NSCLC)是一种罕见的疾病,治疗选择有限,预后不佳。 6月12日,中山大学方文峰、张力及黄岩在《Nature Communications》上发表了题为“Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer”...